Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
domvanalimab + etrumadenant + zimberelimab
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **domvanalimab**, an Fc-silent anti-TIGIT monoclonal antibody designed to block the TIGIT checkpoint, enhancing immune cell activation by preventing TIGIT from inhibiting the immune response. **Etrumadenant** is a dual A2a/A2b adenosine receptor antagonist that prevents adenosine-mediated immunosuppression in the tumor microenvironment, promoting antitumor immunity. **Zimberelimab** is an anti-PD-1 monoclonal antibody that restores T-cell antitumor activity by blocking PD-1. The combination aims to synergistically enhance immune responses against cancer cells.
- Other names
- zimberelimab + domvanalimab + etrumadenant
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on domvanalimab + etrumadenant + zimberelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on domvanalimab + etrumadenant + zimberelimab.